AGGREGATE DATA · ADMINISTRATIVE ACTIVITY
Medicine applications
ΕΟΠΥΥ–ΣΗΠ
September 2018 – 2 October 2026
A descriptive summary of application volume and administrative outcomes from the supplied report. No individual patient data is included.
Recorded applications
Patient records in the report
Reported approval rate among decided applications
Applications by active substance
| Active substance | Reported applications |
|---|---|
| Nintedanib | 1,345 |
| Pirfenidone | 938 |
| Mycophenolate | 359 |
| Other / unspecified* | 100 |
| Total | 2,742 |
*Arithmetic remainder of 100 applications, not a verified pharmacological category. The source reports 97 without a recorded drug; categories need reconciliation with the original spreadsheet.
Recent recorded activity
- 230 applications in 2026 through the export date, according to the summary.
- 149 records with an application within the preceding 270 days: an administrative definition of recent activity.
- Three records include nerandomilast in their treatment sequence. Its application and approval counts have not been verified separately.
Definitions and interpretation limits
- Approval rate: approvals / (approvals + board rejections + negative EOF opinions), according to the source. Cancelled, draft and pending applications are excluded. This is not a treatment-effectiveness measure.
- Renewals count as separate applications. The 2,742 applications do not represent 2,742 different patients.
- No subsequent application does not identify death, transplantation, treatment discontinuation or transfer to another physician. No survival or treatment-persistence curve is presented.
- J84.9 alone does not establish autoimmune ILD or a specific inflammatory phenotype; a confirmed clinical diagnosis is needed.
- 2018 and 2026 are partial years. First appearance in the file does not necessarily mean first diagnosis or first visit.
- Applications do not measure dispensed quantity, adherence or actual cost. The source contains no prices. Name-inferred sex and unverified entry ages are not presented.
Source and verification status
Source: High_Cost_Prescribing_Report_2018-2026.html, reporting an SHP export dated 2 October 2026. Aggregate presentation checked: 11 October 2026. The original spreadsheet was not examined. Scientific use of rates or comparisons requires reconciliation of applications, unique patients, substances and final outcomes.
This summary does not claim scientific review or approval by Professor Demosthenes Bouros.